Heart transplantation and infection

Czech version

Authors: Eva Ozábalová ¹; Jan Krejčí ¹; Petr Hude ¹; Julius Godava ¹; Tomáš Honek ¹; Lenka Špinarová ¹; Petr Pavlík ²; Helena Bedáňová ²; Petr Němec ²
Authors‘ workplace: I. interní kardio-angiologická klinika LF M U a FN u sv. Anny v Brně ¹; Centrum kardiovaskulární a transplantační chirurgie, Brno ²
Published in: Vnitř Lék 2017; 63(7-8): 535-539
Category: Reviews

Overview

Heart transplantation (HTx) is a method of treatment for patients with end-stage heart failure with severe symptoms despite complex therapy. Post-transplant difficulties include acute rejection and infectious complications, which are the most common reason of morbidity and mortality in the first year after heart transplant. It requires the patient to remain on immunosuppressive medication to avoid the possibility of graft rejection. Therefore the range of infection is much larger. The diagnosis and treatment of viral, bacterial and fungal infections is often difficult.

Key words:
heart transplantation – immunosuppression – infection

Sources

1. Lund LH, Edwards LB, Dipchand AI et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation: Report – 2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016; 35(10): 1158–1169. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2016.08.017>.

2. Delgado JF, Sánchez V, de la Calzada CS. Acute rejection after heart transplantation. Expert Opin Pharmacother 2006; 7(9): 1139–1149. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.7.9.1139>.

3. Gurguí M, Muňoz P. Infection in heart transplantation. Enferm Infecc Microbiol Clin 2007; 25(9): 587–597.

4. Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Standford University Medical Center. Clin Infect Dis 2001; 33(5): 629–640.

5. Fishman JA. Infection in solid-organ transplant recipient. NEJM 2007; 357(25): 2601–2614.

6. Sanchez-Lazaro IJ, Almenar L, Blanes M et al. Timing, etiology and location of first infection in first year after heart transplantation. Transplant Proc 2010; 42(8): 3017–3019. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2010.07.052>.

7. Melero-Ferrer J, Sanchez-Lazaro IJ, Navea-Tejerina A et al. Repeated CMV Infection in a Heart Transplantation Patient. Case Rep Transplant 2012; 2012: 305920. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/305920>.

8. Doesch AO. Infections after Heart Transplantation. Transplantationsmedizin 2011; 23: 115–117. Dostupné z WWW: http://www.transplantation.de/fileadmin/transplantation/txmedizin/txmedizin_2011_2/05_doesch.pdf>.

9. Johansonn I, Andersson R, Friman V et al. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC Infect Dis 2015; 15: 582. Dostupné z DOI: <http://dx.doi.org/10.1186/s12879–015–1321–1>.

10. Hummel M. Early postoperative therapy after heart transplantation: Prophylaxis, diagnosis and antibiotic, antimycotic and antiviral therapy of infections. ACP 2011; 15: 245–255.Dostupné z WWW: <http://www.applied-cardiopulmonary-pathophysiology.com/fileadmin/downloads/acp-2011–4_20111229/09_hummel.pdf>.

11. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systemic review of randomised controlled trials. Lancet 2005; 365(9477): 2105–2115.

12. Muñoz P, Rodríguez C, Bouza E et al. Risk Factors of Invasive Aspergillosis after Heart Transplantation:Protective Role of Oral Itraconazole Prophylaxis. Am J of Transpl 2004; 4(4): 636–643.

13. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment – rethinking our approach to prevention. Clin Infect Dis 2001; 33(9): 1549–1552.

14. Gustafson TL, Schaffner W, Lavely G et al. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148(2): 230–238.

15. Ráčil Z, Mayer J, Cetkovský P et al. Invazivní aspergilóza: současné možnosti diagnostiky. Vnitř Lék 2007; 53(Suppl): S1-S34.

16. Taccone FS, Van Den Abeele AM, Bulpa P et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcome. Crit Care 2015; 19: 7. Dostupné z DOI: <http://dx.doi.org/10.1186/s13054–014–0722–7>.

17. Musher B, Fredricks D, Leisenring W et al. Aspergillus Galactomannan Enzyme Immunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage Fluid. J Clin Microbiol 2004; 42(12): 5517–5522.

18. Ráčil Z, Mayer J, Kocmanová I et al. Léčba invazivní aspergilózy – doporučení odborných společností. Vnitř Lék 2008; 54(12): 1187–1194.

19. Denning DW. Therapeutic Outcome in Invasive Aspergillosis. Clin Infect Dis 1996; 23(3): 608–615.

20. Preiksaitis JK, Green M, Avery RK et al. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004; 4(Suppl 10): S5-S166.

21. Pazdernik M, Malek I, Koudelkova E et al. Bone marrow suppression and associated consequences in patients after heart transplantation: A 6-year retrospective review. Biomed Pap Med Fac Univ Palacky Olomouc 2015; 159(3): 372–377. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2015.022>.

22. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89(7): 779–795. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e3181cee42f>.

23. Costanzo MR, Dipchand A, Starling R et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29(8): 914–956. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2010.05.034>.

24. Muňoz P, Crespo Leiro MG. Prophylaxis of cytomegalovirus infection in heart transplantation. Enferm Infecc Microbiol Clin 2011; 29(Suppl 6): S52-S55. Dostupné z DOI: <http://dx.doi.org/10.1016/S0213–005X(11)70059–3>.

25. Sun HY, Wagener M, Singh N. Prevention of posttransplant cytomegalovirus dinase and related outcomes with valganciclovir: a systemic review. Am J of Transpl 2008; 8(10): 2111–2118. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600–6143.2008.02369.x>.

26. Kalil AC, Levitsky J, Lyden E et al. Metaanalysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143(12): 870–880.

27. Cahil BC, Hibbs JR, Savik K et al. Aspergillus Airway Colonization and Invasive Disease After Lung Transplantation. Chest 1997; 112(5): 1160–1164.